Detection of anti-cytokine antibodies and their clinical relevance

References

• Schroeder HW Jr, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol 2010;125(2 Suppl 2):S41-52
   PubMed Web of Science ®Google Scholar
• Wadhwa M, Thorpe R. Unwanted immunogenicity: lessons learned and future challenges. Bioanalysis 2010;2(6):1073-84
   PubMed Web of Science ®Google Scholar
• Mire-Sluis AR, Chen YC, Devanarayan V, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004;289(1-2):1-16
   PubMed Web of Science ®Google Scholar
• Wakshull E, Coleman D. Confirmatory immunogenicity assays. In: Tovey M, editor. Detection and quantification of antibodies to biopharmaceuticals. John Wiley & Sons, Inc; Hoboken, NJ, USA: 2011. p. 103-7
   Google Scholar
• Meager A. RIA, IRMA and ELISA assays for cytokines and their soluble receptors. In: Balkwill FR, editor. Cytokine cell biology: a practical approach. Oxford University Press; Oxford, UK: 2000. p. 193-206
   Google Scholar
• Bendtzen K, Svenson M. Enzyme immunoassays and radioimmunoassays for quantification of anti-TNF biopharmaceuticals and anti-drug antibodies. In: Tovey M, editor. Detection and quantification of antibodies to biopharmaceuticals. John Wiley & Sons, Inc; Hoboken, NJ, USA: 2011. p. 193-209
   Google Scholar
• Zhang L, Barker JM, Babu S, et al. A robust immunoassay for anti-interferon autoantibodies that is highly specific for patients with autoimmune polyglandular syndrome type 1. Clin Immunol 2007;125(2):131-7
   PubMedGoogle Scholar
• Swanson SJ, Jacobs SJ, Mytych D, et al. Applications for the new electrochemiluminescent (ECL) and biosensor technologies. Dev Biol Stand 1999;97:135-47
   PubMedGoogle Scholar
• Cludts I, Meager A, Thorpe R, Wadhwa M. Detection of neutralizing interleukin-17 antibodies in autoimmune polyendocrinopathy syndrome-1 (APS-1) patients using a novel non-cell based electrochemiluminescence assay. Cytokine 2010;50(2):129-37
   PubMed Web of Science ®Google Scholar
• Swanson SJ, Mytych D. The use of surface plasmon resonance for the detection and characterization of antibodies. In: Tovey M, editor. Detection and quantification of antibodies to biopharmaceuticals. John Wiley & Sons, Inc; Hoboken, NJ, USA: 2011. p. 83-101
   Google Scholar
• Oftedal BE, Wolff AS, Bratland E, et al. Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune polyendocrine syndrome type I. Clin Immunol 2008;129(1):163-9
   PubMedGoogle Scholar
• Burbelo PD, Browne SK, Sampaio EP, et al. Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. Blood 2010;116(23):4848-58
   PubMed Web of Science ®Google Scholar
• Wadhwa M, Bird C, Dilger P, et al. Quantitative biological assays for individual cytokines. In: Balkwill F, editor. Cytokine cell biology: a practical approach. Oxford University Press; Oxford, UK: 2000. p. 207-39
   Google Scholar
• Meager A. Measurement of cytokines by bioassays: theory and application. Methods 2006;38(4):237-52
   PubMed Web of Science ®Google Scholar
• Gupta S, Indelicato SR, Jethwa V, et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods 2007;321(1-2):1-18
   PubMed Web of Science ®Google Scholar
• Grossberg SE, Kawade Y. The development and measurement of antibodies to interferon. In: Meager A, editor. The interferons: characterization and application. Wiley-VCH Press; Weinheim, Germany; 2006. p. 375-99
   Google Scholar
• Meager A, Wadhwa M, Bird C, et al. Spontaneously occurring neutralising antibodies against granulocyte - macrophage colony - stimulating factor (GM-CSF) in patients with autoimmune disease. Immunology 1999;97(3):526-32
   PubMed Web of Science ®Google Scholar
• Wadhwa M, Meager A, Dilger P, et al. Neutralizing antibodies to granulocyte colony-stimulating factor, interleukin-1α and interferon-α, but not other cytokines in human immunoglobulin preparations. Immunology 2000;99(1):113-23
   PubMedGoogle Scholar
• European Medicines Agency. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. 2007. Available from: www.EMEA.europa.eu/pdfs/human/biosimilar/1432706en.pdf
   Google Scholar
• Food and Drug Administration. Guidance for industry. Assay development for immunogenicity testing of therapeutic proteins. 2009. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM192750.pdf
   Google Scholar
• Wadhwa M, Thorpe R. Guidance on immunogenicity assessment of biologically derived therapeutic proteins: a European perspective. In: Tovey M, editor. Detection and quantification of antibodies to biopharmaceuticals. John Wiley & Sons; Inc; Hoboken, New Jersey, USA: 2011. p. 37-56
   Google Scholar
• ’t Hart BA, van Kooyk Y. Yin-Yang regulation of autoimmunity by DCs. Trends Immunol 2004;25(7):353-9
   PubMed Web of Science ®Google Scholar
• Mouchess ML, Anderson M. Central tolerance induction. Curr Top Microbiol Immunol 2013;373:69-86
   Google Scholar
• Gupta S, Louis AG. Tolerance and autoimmunity in primary immunodeficiency disease: a comprehensive review. Clin Rev Allergy Immunol 2013;45(2):162-9
   PubMedGoogle Scholar
• Pradeu T, Cooper EL. The danger theory: 20 years later. Front Immunol 2012;3:287
   PubMed Web of Science ®Google Scholar
• Browne SK. Anticytokine autoantibody-associated immunodeficiency. Annu Rev Immunol 2014;32:635-57
   PubMed Web of Science ®Google Scholar
• Bendtzen K, Hansen MB, Ross C, Svenson M. High avidity autoantibodies to cytokines. Immunol Today 1998;19(5):209-11
   PubMedGoogle Scholar
• Meager A, Wadhwa M, Dilger P, et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol 2003;132(1):128-36
   PubMed Web of Science ®Google Scholar
• Caruso A, Turano A. Natural antibodies to interferon gamma. Biotherapy 1997;10:29-37
   PubMedGoogle Scholar
• Watanabe M, Uchida K, Nakagaki K, et al. High avidity cytokine autoantibodies in health and disease: pathogenesis and mechanisms. Cytokine Growth Factor Rev 2010;21(4):263-73
   PubMed Web of Science ®Google Scholar
• Uchida K, Nakata K, Suzuki T, et al. Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood 2009;113(11):2547-56
   PubMed Web of Science ®Google Scholar
• Meager A, Cludts I, Thorpe R, Wadhwa M. Are neutralizing anti-GM-CSF autoantibodies present in all healthy persons? Blood 2010;115(2):433-4
   PubMedGoogle Scholar
• Satoh H, Chizzonite R, Ostrowski C, et al. Characterization of anti-IL-1 alpha autoantibodies in the sera from healthy humans. Immunopharmacology 1994;27(2):107-18
   PubMedGoogle Scholar
• Kurdowska A, Miller EJ, Noble JM, et al. Anti-IL-8 autoantibodies in aveolar fluid from patients with the adult respiratory distress syndrome. J Immunol 1996;157(6):2699-706
   PubMedGoogle Scholar
• Ohmoto Y, Ogushi F, Muraguchi M, et al. Age-related increase of autoantibodies to interleukin-1 alpha in healthy Japanese blood donors. J Med Invest 1997;44(1-2):89-94
   PubMedGoogle Scholar
• Laricchia-Robbio L, Moscato S, Genua A, et al. Naturally occurring and therapy-induced antibodies to human granulocyte colony-stimulating factor (G-CSF) in human serum. J Cell. Physiol 1997;173(2):219-26
   PubMedGoogle Scholar
• de Lemos Rieper C, Galle P, Pedersen BK, Hansen MB. A state of acquired IL-10 deficiency in 0.4% of Danish blood donors. Cytokine 2010;51(3):286-93
   PubMedGoogle Scholar
• Galle P, Svenson M, Bendtzen K, Hansen MB. High levels of neutralizing IL-6 autoantibodies in 0.1% of apparently healthy blood donors. Eur J Immunol 2004;34(11):3267-75
   PubMedGoogle Scholar
• Puel A, Döffinger R, Natividad A, et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 2010;207(2):291-7
   PubMed Web of Science ®Google Scholar
• Kisand K, Bøe Wolff AS, Trebušak Podkrajšek K, et al. Chronic mucocutaneous candidiasis in APECED or thymoma correlates with autoimmunity to Th17-associated cytokines. J Exp Med 2010;207(2):299-308
   PubMed Web of Science ®Google Scholar
• Ross C, Svenson M, Hansen MB, et al. High avidity IFN antibodies in pharmaceutically prepared human IgG. J Clin Invest 1995;95(5):1974-8
   PubMedGoogle Scholar
• Pozzetto B, Mogensen KE, Tovey MG, Gresser I. Characteristics of autoantibodies to human interferon in a patient with varicella-zoster disease. J Infect Dis 1984;150(5):707-13
   PubMedGoogle Scholar
• Ross C, Svenson M, Nielsen H, et al. Increased in vivo antibody activity against interferon alpha, interleukin-1 alpha, and interleukin-6 after high dose Ig therapy. Blood 1997;90(6):2376-80
   PubMedGoogle Scholar
• Perheentupa J. APS-1/APECED: the clinical disease and therapy. Endocrinol Metab Clin North Am 2002;31(2):295-320
   PubMed Web of Science ®Google Scholar
• Gallo V, Giardino G, Capalbo D, et al. Alterations of the autoimmune regulator transcription factor and failure of central tolerance: APECED as a model. Expert Rev Clin Immunol 2013;9(1):43-51
   PubMed Web of Science ®Google Scholar
• Willcox N, Sheppard M, Loehrer PJ. Thymic tumours and their autoimmune associations. In: Souhami RL, Tannock I, Hohenberger P, Horiot JC, editors. Oxford textbook of oncology. 2nd edition. Oxford University Press; Oxford, UK: 2002. p. 2143-52
   Google Scholar
• Ströbel P, Murumagi A, Klein R, et al. Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendo-crinopathy syndrome type 1 (APS-1). J Pathol 2007;211(5):563-71
   PubMedGoogle Scholar
• Meager A, Visvalingam K, Peterson P, et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med 2006;3(7):1152-64
   Google Scholar
• Meager A, Peterson P, Willcox N. Hypothetical review: thymic aberrations and type-I interferons: attempts to deduce autoimmunizing mechanisms from unexpected clues in monogenic and paraneoplastic syndromes. Clin Exp Immunol 2008;154(1):141-51
   PubMedGoogle Scholar
• Kärner J, Meager A, Laan M, et al. Anti-cytokine autoantibodies suggest pathogenetic links with autoimmune regulator deficiency in humans and mice. Clin Exp Immunol 2013;171(3):263-72
   PubMedGoogle Scholar
• Wolff ASB, Sarkadi AK, Maródi L, et al. Anti-cytokine autoantibodies preceding onset of autoimmune polyendocrine syndrome type I features in early childhood. J Clin Immunol 2013;33(8):1341-8
   PubMed Web of Science ®Google Scholar
• Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358(9):929-39
   PubMed Web of Science ®Google Scholar
• Rönnblom L, Alm GV, Eloranta ML. The type I interferon system in the development of lupus. Semin Immunol 2011;23(2):113-21
   PubMed Web of Science ®Google Scholar
• Ching KH, Burbelo PD, Tipton C, et al. Two major autoantibody clusters in systemic lupus erythematosus. PLoS One 2012;7(2):e32001
   Google Scholar
• Prümmer O, Seyfarth C, Scherbaum W, et al. Interferon-alpha antibodies in autoimmune diseases. J Interferon Res 1989;9(Suppl 1):S67-74
   PubMedGoogle Scholar
• Prümmer O, Frickhofen N, Digel W, et al. Spontaneous interferon-alpha antibodies in a patient with pure red cell aplasia and recurrent cutaneous carcinomas. Ann Hematol 1991;62(2-3):76-80
   PubMedGoogle Scholar
• Prümmer O, Zillikens D, Porzsolt F. High-titer interferon-alpha antibodies in a patient with pemphigus foliaceus. Exp Dermatol 1996;5(4):213-17
   PubMedGoogle Scholar
• Trown P, Kramer M, Dennin RJ, et al. Antibodies to human leucocyte interferons in cancer patients. Lancet 1983;1:81-4
   Google Scholar
• Prümmer O, Bunjes D, Wiesneth M, et al. Antibodies to interferon-alpha: a novel type of autoantibody after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996;17(4):617-23
   PubMedGoogle Scholar
• Ikeda Y, Toda G, Hashimoto N, et al. Naturally occurring anti-interferon-alpha 2a antibodies in patients with acute viral hepatitis. Clin Exp Immunol 1991;85(1):80-4
   PubMedGoogle Scholar
• Fall LS, Chams V, Le Coq H, et al. Evidence for an antiviral effect and interferon neutralizing capacity in human sera; variability and implications for HIV infection. Cell Mol Biol (Noisy-le-grand) 1995;41(3):409-16
   PubMedGoogle Scholar
• Meloni A, Furcas M, Cetani F, et al. Autoantibodies against type I Interferons as an additional diagnostic criteria for Autoimmune Polyendocrine Syndrome type I. J Clin Endocrinol Metab 2008;93(11):4389-97
   PubMed Web of Science ®Google Scholar
• Kisand K, Link M, Bøe Wolff AS, et al. Interferon autoantibodies associated with AIRE-deficiency decrease the expression of IFN-stimulated genes. Blood 2008;112(7):2657-66
   PubMedGoogle Scholar
• Morimoto AM, Flesher DT, Yang J, et al. Association of endogenous anti-interferon-alpha autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63(8):2407-15
   PubMedGoogle Scholar
• Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical efficacy of silalimumab, a fully human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis 2011;11):1905-13
   PubMedGoogle Scholar
• Kluger N, Krohn K, Ranki A. Absence of some common organ-specific and non-organ-specific autoimmunity in autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. Endocr Connect 2013;2(1):61-8
   PubMedGoogle Scholar
• Wang W, Milani M, Ostlie N, et al. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells. J Immunol 2007;178(11):7072-80
   PubMed Web of Science ®Google Scholar
• Puel A, Ricard C, Cypowyj S, et al. Inborn errors of mucocutaneous immunity to Candida albicans: a role for IL-17 cytokines? Curr Opin Immunol 2010;22(1):1-8
   PubMedGoogle Scholar
• Kisand K, Lilic D, Casanova JL, et al. Mucocutaneous candidiasis and autoimmunity against cytokines in APECED and thymoma patients: clinical and pathogenetic implications. Eur J Immunol 2011;41(6):1517-27
   PubMed Web of Science ®Google Scholar
• Patel SY, Ding L, Brown MR, et al. Anti-IFN-gamma autoantibodies in disseminated nontuberculous mycobacterial infections. J Immunol 2005;175(7):4769-76
   PubMedGoogle Scholar
• Kampitak T, Suwanpimolkul G, Browne S, Suankratay C. Anti-interferon-γ autoantibody and opportunistic infections: case series and review of the literature. Infection 2011;39(1):65-71
   PubMedGoogle Scholar
• Browne SK, Burbelo PD, Chetchotisakd P, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med 2012;367(8):725-34
   PubMed Web of Science ®Google Scholar
• Chi CY, Chu CC, Liu JP, et al. Anti-IFN-γ autoantibodies in adults with disseminated nontuberculous mycobacterial infections are associated with HLA-DRB1*16:02 and HLA-DQB1*05:02 and the reactivation of latent varicella-zoster virus infection. Blood 2013;121(8):1357-66
   PubMedGoogle Scholar
• Puel A, Casanova JL. Autoantibodies against cytokines: back to human genetics. Blood 2013;121(8):1246-7
   PubMedGoogle Scholar
• Graudal NA, Svenson M, Tarp U, et al. Autoantibodies against interleukin 1 alpha in rheumatoid arthritis: association with long term radiographic outcome. Ann Rheum Dis 2002;61(7):598-602
   PubMedGoogle Scholar
• Jouvenne P, Fossiez F, Banchereau J, Moissec P. High levels of neutralizing autoantibodies against IL-1 alpha are associated with a better prognosis in chronic polyarthritis: a follow-up study. Scand J Immunol 1997;46(4):413-18
   PubMedGoogle Scholar
• Mizutani H, Ohmoto Y, Kupper TS, Shimizu M. Endogenous neutralizing anti-IL-1 autoantibodies in inflammatory skin diseases: possible natural inhibitor for over expressed epidermal IL-1. J Dermatol Sci 1998;20(1):63-71
   PubMedGoogle Scholar
• Maniwa K, Ogushi F, Tani K, et al. Increased incidence of autoantibodies to interleukin-1a in rheumatoid arthritis with interstitial lung disease. Respirology 2000;5(4):315-20
   PubMedGoogle Scholar
• Ogushi F, Tani K, Endo T, et al. Autoantibodies to IL-1 alpha in sera from rapidly progressive idiopathic pulmonary fibrosis. J Med Invest 2001;48(3-4):181-9
   PubMedGoogle Scholar
• Pedersen M, Permin H, Bindslev-Jensen C, et al. Cytokine-induced histamine release from basophils of AIDS patients. Interactions between cytokines and specific IgE antibodies. Allergy 1991;46(2):129-34
   PubMedGoogle Scholar
• Bost KL, Hahn BH, Saag MS, et al. Individuals infected with HIV possess antibodies against IL-2. Immunology 1988;65(4):611-15
   PubMedGoogle Scholar
• Ebert EC, Panja A, Das KM, et al. Patients with inflammatory bowel disease may have a transforming growth factor-beta-, interleukin (IL)-2- or IL-10-deficient state induced by intrinsic neutralizing antibodies. Clin Exp Immunol 2009;155(1):65-71
   PubMedGoogle Scholar
• Mostbock S. Cytokine/antibody complexes: an emerging class of immunostimulants. Curr Pharm Des 2009;15(7):809-25
   PubMed Web of Science ®Google Scholar
• Elkarim RA, Mustafa M, Kivisakk P, et al. Cytokine autoantibodies in multiple sclerosis, aseptic meningitis and stroke. Eur J Clin Invest 1998;28(4):295-9
   PubMed Web of Science ®Google Scholar
• Elkarim R, Granert C, Lindquist L, et al. Levels of gamma interferon and interleukin-4 are inversely related to the levels of their corresponding autoantibodies in patients with lower respiratory tract infection. Infect Immun 1999;67(6):3051-4
   PubMedGoogle Scholar
• Takemura H, Susuki H, Yoshizaki K, et al. Anti-interleukin-6 autoantibodies in rheumatic diseases. Increased frequency in sera of patients with systemic sclerosis. Arthritis Rheum 1992;35(8):940-3
   PubMedGoogle Scholar
• Suzuki H, Takemura H, Yoshizaki K, et al. IL-6-anti-IL-6 autoantibody complexes with IL-6 activity in sera from some patients with systemic sclerosis. J Immunol 1994;152(2):935-42
   PubMedGoogle Scholar
• Puel A, Picard C, Lorrot M, et al. Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J Immunol 2008;180(1):647-54
   PubMedGoogle Scholar
• Homann C, Hansen MB, Graudal N, et al. Anti-interleukin-6 autoantibodies in plasma are associated with an increased frequency of infections and increased mortality of patients with alcoholic cirrhosis. Scand J Immunol 1996;44(6):623-9
   PubMedGoogle Scholar
• Nanki T, Onoue I, Nagasaka K, et al. Suppression of elevations in serum C reactive protein levels by anti-IL-6 autoantibodies in two patients with severe bacterial infections. Ann Rheum Dis 2013;72(6):1100-2
   PubMed Web of Science ®Google Scholar
• Fudula R, Krupa A, Stankowska D, et al. Anti-interleukin-8 autoantibody:interleukin-8 immune complexes in acute lung injury/acute respiratory distress syndrome. Clin Sci (Lond) 2008;114(6):403-12
   PubMedGoogle Scholar
• Fudula R, Krupa A, Matthay MA, et al. Anti-IL-8 autoantibody: IL-8 immune complexes suppress spontaneous apoptosis of neutrophils. Am J Physiol Lung Cell Mol Physiol 2007;293(2):L364-74
   Google Scholar
• Fudala R, Krupa A, Stankowska D, et al. Does activation of the FcgammaRIIa play a role in the pathogenesis of the acute lung injury/acute respiratory distress syndrome? Clin Sci (Lond) 2010;118(8):519-26
   PubMedGoogle Scholar
• Lokshin AE, Winans M, Landsittel D, et al. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol 2006;102(2):244-51
   PubMed Web of Science ®Google Scholar
• Hellmich B, Csernok E, Schatz H, et al. Autoantibodies against granulocyte colony-stimulating factor in Felty’s syndrome and neutropenic systemic lupus erythematosus. Arthritis Rheum 2002;46(9):2384-91
   PubMedGoogle Scholar
• Uchida K, Nakata K, Trapnell BC, et al. High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood 2004;103(3):1089-98
   PubMed Web of Science ®Google Scholar
• Trapnell BC, Carey BC, Uchida K, Suzuki T. Pulmonary alveolar proteinosis, a primary immunodeficiency of impaired GM-CSF stimulation of macrophages. Curr Opin Immunol 2009;21(5):514-21
   PubMed Web of Science ®Google Scholar
• Bendtzen K, Svenson M, Hansen MB. GM-CSF autoantibodies in pulmonary alveolar proteinosis. N Engl J Med 2007;356(19):2001
   PubMedGoogle Scholar
• Sjöwall C, Ernerudh J, Bengtsson AA, et al. Reduced anti-TNFalpha autoantibody levels coincide with flare in systemic lupus erythematosus. J Autoimmun 2004;22(4):315-23
   PubMedGoogle Scholar
• Rosenau BJ, Schur PH. Autoantibodies to tumor necrosis factor in patients with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 2009;36(4):753-6
   PubMedGoogle Scholar
• Sjöwall C, Kastbom A, Almroth G, et al. Beware of antibodies to dietary proteins in "antigen-specific" immunoassays! falsely positive anticytokine antibody tests due to reactivity with bovine serum albumin in rheumatoid arthritis (the Swedish TIRA project). J Rheumatol 2011;38(2):215-20
   PubMed Web of Science ®Google Scholar
• Antonelli G Antibodies to interferon in patients undergoing IFN therapy: an update. J Biol Regul Homeost Agents 1995;9(4):123-31
   PubMedGoogle Scholar
• Antonelli G, Simeoni E, Currenti M, et al. Interferon antibodies in patients with infectious diseases. Biotherapy 1997;10(1):7-14
   PubMedGoogle Scholar
• Meager A. Development and characterisation of spontaneous and therapy-induced antibodies to interferons. In: Chadha KC, editor. Interferons: current status. Research Signpost; Kerala, India: 2007. p. 265-92
   Google Scholar
• Antonelli G, Bellomi F, Turriziani O, et al. In vivo development of antibody to IFNs in IFN-treated patients. In: Chadha KC, editor. Interferons: current status. Research Signpost; Kerala, India: 2007. p. 293-309
   Google Scholar
• Hou C, Chuang WL, Yu ML, et al. Incidence and associated factors of neutralizing anti-interferon antibodies among chronic hepatitis C patients treated with interferon in Taiwan. Scand J Gastroenterol 2000;35(12):1288-93
   PubMed Web of Science ®Google Scholar
• Antonelli G, Currenti M, Turrizani O, Dianzani F. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis 1991;163(4):882-5
   PubMedGoogle Scholar
• Simon DM, Gordon SC, Kaplan MM, et al. Treatment of chronic hepatitis C with interferon alfa-n3: a multi-center, randomized, open-label trial. Hepatology 1997;25(2):445-8
   PubMedGoogle Scholar
• Tovey MG, Lallemand C. Safety, tolerability and immunogenicity of interferons. Pharmaceuticals 2010;3:1162-86
   Google Scholar
• McKenna RM, Oberg KE. Antibodies to interferon-alpha in treated cancer patients: incidence and significance. J Interferon Cytokine Res 1997;17(3):141-3
   PubMedGoogle Scholar
• Brand CM, Leadbeater L, Budiman R, et al. Successful re-treatment of an anti-interferon resistant polycythaemia vera patient with lymphoblastoid interferon-alpha N1 and in vitro studies on the specificity of the antibodies. Br J Haematol 1994;86(1):216-18
   PubMedGoogle Scholar
• Casato M, Antonelli G, Maggi F, et al. Resistance to recombinant alpha interferon therapy in idiopathic mixed cryoglobulinemia: reinduction of remission by natural alpha interferon both in antibody-positive and -negative patients. J Biol Regul Homeost Agents 1994;8(2):56-9
   PubMedGoogle Scholar
• Foster GR. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs 2010;70(2):147-65
   PubMedGoogle Scholar
• Degasperi E, Viganò M, Aghemo A, et al. PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history. Expert Rev Anti Infect Ther 2013;11(5):459-74
   PubMed Web of Science ®Google Scholar
• Scagnolari C, Trombetti S, Soldà A, et al. Development and specificities of anti-interferon neutralizing antibodies in patients with chronic hepatitis C treated with pegylated interferon-α. Clin Microbiol Infect 2012;18(10):1033-9
   PubMedGoogle Scholar
• Jacobs I, Goodkin DE, Rudick RA, Herndon R. Advances in specific therapy for multiple sclerosis. Curr Opin Neurol 1994;7(3):250-4
   PubMedGoogle Scholar
• Goodin DS. Treatment of multiple sclerosis with human beta interferon. Int MS J 2005;12(3):96-108
   PubMedGoogle Scholar
• Clerico M, Contessa G, Durelli L. Interferon-beta1-a for the treatment of multiple sclerosis. Expert Opin Biol Ther 2007;7(4):535-42
   PubMed Web of Science ®Google Scholar
• Meager A, Dolman C, Dilger P, et al. An assessment of biological potency and molecular characteristics of different innovator and non-innovator interferon-beta products. J Interferon Cytokine Res 2011;31(4):383-1392
   PubMed Web of Science ®Google Scholar
• Rinehart J, Malspies L, Young D, Neidhart J. Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma. Cancer Res 1986;46(10):5364-7
   PubMedGoogle Scholar
• Bertolotto A, Deisenhammer F, Gallo P, et al. Immunogenicity of interferon beta: differences among products. J Neurol 2004;251(Suppl 2):II15-24
   PubMedGoogle Scholar
• Sominanda A, Rot U, Suoniemi M, et al. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult Scler 2007;13(2):208-14
   PubMedGoogle Scholar
• Meager A. Cell-based assays for the detection of neutralizing antibodies to interferon beta (IFNβ) and tumor necrosis factor alpha (TNFα) inhibitors. In: Tovey M, editor. Detection and quantification of antibodies to biopharmaceuticals. John Wiley & Sons, Inc; Hoboken, NJ, USA: 2011. p. 133-56
   Google Scholar
• Wadhwa M, Subramanyam M, Goelz S, et al. Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-β. J Interferon Cytokine Res 2013;33(11):660-71
   PubMedGoogle Scholar
• Cludts I, Meager A, Thorpe R, Wadhwa M. Development and characterization of a non-cell-based assay to assess the presence of neutralizing antibodies to interferon-beta in clinical samples. J Immunol Methods 2013;395(1-2):37-44
   PubMedGoogle Scholar
• Scagnolari C, Bellomi F, Turriziani O, et al. Neutralizing and binding antibodies to IFN-beta: relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-beta preparations. J Interferon Cytokine Res 2002;22(2):207-13
   PubMedGoogle Scholar
• Gneiss C, Reindl M, Berger T, et al. Epitope specificity of neutralizing antibodies against IFN-beta. J Interferon Cytokine Res 2004;24(5):283-90
   PubMed Web of Science ®Google Scholar
• Farrell RA, Giovannoni G. Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis. Mult Scler 2007;13(5):567-77
   PubMedGoogle Scholar
• Deisenhammer F. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. CNS Drugs 2009;23(5):379-96
   PubMed Web of Science ®Google Scholar
• Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis. Mult Scler 2009;15(5):601-5
   PubMedGoogle Scholar
• van der Voort LF, Visser A, Knol DL, et al. Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosis. Eur J Neurol 2009;16(9):1049-52
   PubMed Web of Science ®Google Scholar
• Pachner AR, Cadavid D, Wolansky L, Skurnick J. Effect of anti-IFN {beta} antibodies on MRI lesions of MS patients in the BECOME study. Neurology 2009;73(18):1485-92
   PubMed Web of Science ®Google Scholar
• Gneiss C, Koudouovoh-Tripp PM, Roplell S, et al. Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study (ASS). Mult Scler 2009;15(12):1481-8
   PubMedGoogle Scholar
• Khan OA, Dhib-Jalbut SS. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive. Neurology 1998;51(6):1698-702
   PubMed Web of Science ®Google Scholar
• Murray HW. Current and future clinical applications of interferon-gamma in host antimicrobial defense. Intensive Care Med 1996;22(Suppl 4):S456-61
   PubMedGoogle Scholar
• Reljic R. IFN-gamma therapy of tuberculosis and related infections. J Interferon Cytokine Res 2007;27(5):353-64
   PubMed Web of Science ®Google Scholar
• Prümmer O, Fiehn C, Gallati H. Anti-interferon-gamma antibodies in a patient undergoing interferon-gamma treatment for systemic mastocytosis. J Interferon Cytokine Res 1996;16(7):519-22
   PubMedGoogle Scholar
• Metcalf D. Hematopoietic cytokines. Blood 2008;111(2):485-91
   PubMed Web of Science ®Google Scholar
• Ragnhammar P, Wadhwa M. Neutralising antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy. Med Oncol 1996;13(3):161-6
   PubMedGoogle Scholar
• Wadhwa M, Skog AL, Bird C, et al. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Clin Cancer Res 1999;5(6):1353-61
   PubMed Web of Science ®Google Scholar
• Zagury D, Le Buanec H, Bizzini B, et al. Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases. Cytokine Growth Factor Rev 2003;14(2):123-37
   PubMedGoogle Scholar
• Ratsimandresy RA, Rappaport J, Zagury JF. Anti-cytokine therapeutics: history and update. Curr Pharm Des 2009;15(17):1998-2025
   PubMed Web of Science ®Google Scholar
• Malekzadeh A, de Groot V, Beckerman H, et al. Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases. Methods 2012;56(4):508-13
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Ashton L, Zhang Y, et al. Comparison of a new multiplex binding assay versus the enzyme-linked immunosorbent assay for measurement of serotype-specific pneumococcal capsular polysaccharide IgG. Clin Vaccine Immunol 2011;18(10):1744-51
   PubMedGoogle Scholar
• Pui TS, Agarwal A, Ye F, et al. Nanoelectronic detection of triggered secretion of pro-inflammatory cytokines using CMOS compatible silicon nanowires. Biosens Bioelectron 2011;26(5):2746-50
   PubMedGoogle Scholar